Another chain-store pharmacy is being investigated for distributing “too much” oxycodone.
The DEA’s expectations for policing pharmacies and their patients who request controlled substances are unclear.
The quest for more effective treatments may lead to questionable off-label prescribing.
It’s time to end the confusing practice of putting “Use as directed” on prescriptions.
Many factors contribute to why reported drug shortages are at their highest levels in more than a decade.
Does prohibiting off-label promotion of drugs violate commercial free speech?
The FDA has continually questioned the traditional compounding of veterinary drugs.
As health care professionals, pharmacists must be cautious when sharing information online.
A recent Supreme Court ruling means that generic manufacturers cannot be held liable for inadequate warning labels.
The Supreme Court has ruled that state attempts to restrict this practice are unconstitutional.
It is misleading to believe that restricted access programs for
prescription drugs will not result in more responsibility for
pharmacists.
Should pharmaceutical company CEOs be held accountable for off-label promotion of their products?
A zero-tolerance policy toward possession of a controlled substance has unintended consequences.
Squabbling between two professors at a college of pharmacy escalates into a major lawsuit.
This month’s case reveals an embezzlement scheme involving a pharmacist’s trusted accountant.
Plaintiffs in pharmacy malpractice cases have begun with increasing
frequency to ask for extra money designed to punish the defendants for
their conduct.
There has been much debate in the pharmacy world over whether this practice is lawful or not.
Do pharmacists have a duty to warn patients about the dangers associated with the use of a prescription medication?
When is a pharmacy responsible for the wrongful actions of its employees?
We must not allow a few bad apples to spoil the integrity of the pharmacy profession.
For more articles, please check our archives.